Therapeutic Plasma Exchange Eased Refractory MG
Therapeutic plasma exchange improved symptoms related to hard-to-treat myasthenia gravis, resulted in reduced use of immunosuppressants, and was well-tolerated…
Articles by Forest Ray PhD
Ultomiris Helps Ease gMG Symptoms in Ongoing Phase 3 Trial
Ultomiris (ravulizumab-cwvz) rapidly and sustainably eased symptom severity in adults with generalized myasthenia gravis (gMG), according to top-line data…
Patient Dosing Begins in Phase 1/2a Trial of Oral NMD670
Patient dosing has begun in a Phase 1/2a clinical trial of NMD670, an investigational oral therapy by NMD…
Single, Low-dose Course of Rituximab Treats MuSK-MG, Pilot Study Suggests
A single, two-day and low-dose course of rituximab can effectively treat patients with muscle-specific tyrosine kinase myasthenia gravis…
Too Much Pyridostigmine May Increase Overactive Bladder Issues
High pyridostigmine doses cause overactive bladder issues in people with myasthenia gravis (MG), according to a recent study.
MG May Mimic Stroke Symptoms, Case Report Suggests
Myasthenia gravis (MG) can mimic the symptoms of a stroke and should not be ruled out even in younger…
Double-Seropositive MG May Be Subtype of MuSK-MG, Study Suggests
A lesser known variety of myasthenia gravis (MG), called double-seropositive, appears to be a subtype of MuSK-antibody positive MG,…
COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
Trusted Sources May Help Ease COVID-19-related Anxiety in MG Patients, Survey Reveals
People with myasthenia gravis (MG) felt high anxiety regarding COVID-19, experienced changes in their interactions with healthcare systems,…
App-Based Study Launched to Gain Better Understanding of Myasthenia Gravis
UCB Biopharma and doc.ai have launched a digital trial aimed at improving the speed and accuracy of diagnosis…